Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 51 to 60 of 176 total matches.
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
cypionate – generic 1, 10 mL vials (100, 200 mg/mL)4,5 50-400 mg IM q2-4 weeks $74.90
Depo-Testosterone ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
Dosage Cost1
Armodafinil – generic C-IV 50, 150, 200, 250 mg tabs EDS: 150-250 mg once/day2 $65.90 ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
, 100, 200 mg tabs 200-300 mg/day PO divided bid8 7.00
15, 25 mg caps 318.00
Topamax (Janssen) 25, 50 ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
/200, 90/400 mg tabs; 90/400 mg once/day x 12 weeks4 36,000.00
Harvoni (Gilead) 33.75/180, 45/200 mg ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
mL, 200 mg/2mL single-dose vials
Dosage 350 mg x 1, then 700 mg at week 4, then 1,050 mg at week 8 ...
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 doi:10.58347/tml.2024.1708e | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
Agent
Ipratropium – Atrovent HFA 17 mcg/inh HFA MDI (200 inh/unit) 2 inh qid PRN $472.10
(Boehringer ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
(Valeant)
25 mg tabs 50-200 mg once/day
or divided bid
291.60
1466.60
Furosemide – generic
Lasix ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
prolongation has been reported with the drug.
A 30-day supply of Braftovi costs $12,200.
significantly longer ...
The FDA has approved the oral kinase inhibitor
encorafenib (Braftovi – Pfizer), in combination with
the epidermal growth factor receptor (EGFR) inhibitor
cetuximab (Erbitux), for treatment of adults with
metastatic colorectal cancer (CRC) with a BRAF
V600E mutation. Encorafenib was approved in 2018
for use with the mitogen-activated kinase (MEK)
inhibitor binimetinib (Mektovi) for treatment of
unresectable or metastatic melanoma with a BRAF
V600E or V600K mutation.
Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
from 200 mg once daily to 300 mg and those ...
The Bruton's tyrosine kinase (BTK) inhibitor
pirtobrutinib (Jaypirca – Lilly) has received
accelerated approval from the FDA for treatment of
relapsed or refractory mantle cell lymphoma (MCL) in
adults who received ≥2 prior lines of systemic therapy,
including a BTK inhibitor. Accelerated approval was
based on the response rate. The BTK inhibitors
ibrutinib (Imbruvica), acalabrutinib (Calquence),
and zanubrutinib (Brukinsa) are also approved for
treatment of MCL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e35-6 doi:10.58347/tml.2023.1670f | Show Introduction Hide Introduction
Ribociclib (Kisqali) for Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
is supplied in 200-mg tablets. The recommended
dosage for treatment of early breast cancer is 400 mg
taken ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
ribociclib (Kisqali – Novartis), which was approved by
the FDA in 2017 for use with an aromatase inhibitor
or fulvestrant for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative advanced or metastatic breast
cancer, has now been approved for use with an
aromatase inhibitor for adjuvant treatment of HR-positive,
HER2-negative stage II or III early breast
cancer at high risk of recurrence. Kisqali can be used in
patients with node-positive or node-negative disease.
The CDK 4/6...
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e202-3 doi:10.58347/tml.2024.1717f | Show Introduction Hide Introduction